Multifocal Motor Neuropathy Associated With Infliximab A Case Report and a Literature Review

Bayrak A. O., Ulusoy H., Bolat N., Doğan B., Ozbenli T.

NEUROLOGIST, vol.22, no.4, pp.144-146, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.1097/nrl.0000000000000132
  • Journal Name: NEUROLOGIST
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.144-146
  • Keywords: multifocal motor neuropathy, infliximab, tumor necrosis factor-alpha blocker, RHEUMATOID-ARTHRITIS, CONDUCTION BLOCK, DISEASE, PATIENT
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Multifocal motor neuropathy with conduction block (MMNCB) is purely a motor neuropathy with progressive weakness that is characteristically caused by conduction blocks. Association with anti-ganglioside antibodies and a good response to immunomodulating therapies suggest an autoimmune etiology. In rare cases, MMN-CB has been reported as an adverse effect of infliximab, a tumor necrosis factor-alpha blocker. We present a case of MMN-CB due to infliximab in a 45-year-old man with psoriatic arthritis who was exposed to the drug for 2 years because of a delayed diagnosis. We emphasize the possibility of this adverse effect and the importance of detailed electrophysiological examinations, which is supported by a review of the literature.